Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 4, Issue 18
September 22 2020
Issue Cover

Table of Contents

EXCEPTIONAL CASE REPORTS

COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
Clinical Trials & Observations
Zahidee Rodriguez,Andi L. Shane,Hans Verkerke,Christopher Lough,Matthew G. Zimmerman,Mehul Suthar,Jens Wrammert,Heather MacDonald,Michael Wolf,Shanelle Clarke,John D. Roback,Connie M. Arthur,Sean R. Stowell,Cassandra D. Josephson
View Articletitled, COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia
Clinical Trials & Observations
Lia Phillips,Jovana Pavisic,Dominder Kaur,N. Valerio Dorrello,Larisa Broglie,Nobuko Hijiya
View Articletitled, Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia
Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization
Clinical Trials & Observations
Ming Y. Lim,Jeffrey A. Gilreath
View Articletitled, Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization

STIMULUS REPORTS

Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source
Clinical Trials & Observations
Zheng Zhang,Stephen J. Schuster,Simon F. Lacey,Michael C. Milone,Dimitri Monos,Vijay G. Bhoj
View Articletitled, Stable HLA antibodies following sustained CD19<sup>+</sup> cell depletion implicate a long-lived plasma cell source
Drag-reducing polymers improve hepatic vaso-occlusion in SCD mice
Dan Crompton,Ravi Vats,Tirthadipa Pradhan-Sundd,Prithu Sundd,Marina V. Kameneva
View Articletitled, Drag-reducing polymers improve hepatic vaso-occlusion in SCD mice
Supplemental data
Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing
Fabienne Lucas,Phillip D. Michaels,Dahai Wang,Annette S. Kim
View Articletitled, Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing
Supplemental data
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib
Paul J. Hampel,Hua-Jay J. Cherng,Timothy G. Call,Wei Ding,Mahsa Khanlari,Ellen D. McPhail,Roberto N. Miranda,Pei Lin,Hussein A. Tawbi,Alessandra Ferrajoli,William G. Wierda,Nitin Jain,Sameer A. Parikh
View Articletitled, Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib
Supplemental data
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström’s macroglobulinemia
Cristina Jiménez,Lian Xu,Nickolas Tsakmaklis,Maria G. Demos,Amanda Kofides,Gloria G. Chan,Maria Luisa Guerrera,Jiaji G. Chen,Xia Liu,Manit Munshi,Christopher J. Patterson,Guang Yang,Jorge J. Castillo,Steven P. Treon,Zachary R. Hunter
View Articletitled, Comparative genomics of <em>CXCR4</em><sup><em>MUT</em></sup> and <em>CXCR4</em><sup><em>WT</em></sup> single cells in Waldenström’s macroglobulinemia
Supplemental data

REVIEW ARTICLES

Systems-based hematology: highlighting successes and next steps
Jori E. May,Patrick C. Irelan,Kailee Boedeker,Emily Cahill,Steven Fein,David A. Garcia,Lisa K. Hicks,Janice Lawson,Ming Y. Lim,Colleen T. Morton,Anita Rajasekhar,Satish Shanbhag,Marc S. Zumberg,Robert M. Plovnick,Nathan T. Connell
View Articletitled, Systems-based hematology: highlighting successes and next steps
Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?
Emery H. Bresnick,Mabel M. Jung,Koichi R. Katsumura
View Articletitled, Human <em>GATA2</em> mutations and hematologic disease: how many paths to pathogenesis?

SYSTEMATIC REVIEW

Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism
Parth Patel,Payal Patel,Meha Bhatt,Cody Braun,Housne Begum,Wojtek Wiercioch,Jamie Varghese,David Wooldridge,Hani Alturkmani,Merrill Thomas,Mariam Baig,Waled Bahaj,Rasha Khatib,Rohan Kehar,Rakesh Ponnapureddy,Anchal Sethi,Ahmad Mustafa,Wendy Lim,Grégoire Le Gal,Shannon M. Bates,Linda B. Haramati,Jeffrey Kline,Eddy Lang,Marc Righini,Mohamad A. Kalot,Nedaa M. Husainat,Yazan Nayif Al Jabiri,Holger J. Schünemann,Reem A. Mustafa
View Articletitled, Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Clinical Trials & Observations
Gerwin Huls,Dana A. Chitu,Thomas Pabst,Saskia K. Klein,Georg Stussi,Laimonas Griskevicius,Peter J. M. Valk,Jacqueline Cloos,Arjan A. van de Loosdrecht,Dimitri Breems,Danielle van Lammeren-Venema,Isabelle van Zeventer,Rinske Boersma,Mojca Jongen-Lavrencic,Martin Fehr,Mels Hoogendoorn,Markus G. Manz,Maaike Söhne,Rien van Marwijk Kooy,Dries Deeren,Marjolein W. M. van der Poel,Marie Cecile Legdeur,Lidwine Tick,Yves Chalandon,Emanuele Ammatuna,Sabine Blum,Bob Löwenberg,Gert J. Ossenkoppele,for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK),for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
View Articletitled, Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Supplemental data
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Clinical Trials & Observations
Stephen T. Oh,Moshe Talpaz,Aaron T. Gerds,Vikas Gupta,Srdan Verstovsek,Ruben Mesa,Carole B. Miller,Candido E. Rivera,Angela G. Fleischman,Swati Goel,Mark L. Heaney,Casey O’Connell,Murat O. Arcasoy,Yafeng Zhang,Jun Kawashima,Tomas Ganz,Mark Kowalski,Carrie Baker Brachmann
View Articletitled, ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Supplemental data
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma
Clinical Trials & Observations
Wen-Kai Weng,Sally Arai,Andrew Rezvani,Laura Johnston,Robert Lowsky,David Miklos,Judith Shizuru,Lori Muffly,Everett Meyer,Robert S. Negrin,Erica Wang,Timothy Almazan,Lynn Million,Michael Khodadoust,Shufeng Li,Richard T. Hoppe,Youn H. Kim
View Articletitled, Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome
Iosifina P. Foskolou,Laura Barbieri,Aude Vernet,David Bargiela,Pedro P. Cunha,Pedro Velica,Eunyeong Suh,Sandra Pietsch,Rugile Matuleviciute,Helene Rundqvist,Dominick McIntyre,Ken G. C. Smith,Randall S. Johnson
View Articletitled, The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome
Supplemental data
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Kodandaram Pillarisetti,Gordon Powers,Leopoldo Luistro,Alexander Babich,Eric Baldwin,Yingzhe Li,Xiaochun Zhang,Mark Mendonça,Nate Majewski,Rupesh Nanjunda,Diana Chin,Kathryn Packman,Yusri Elsayed,Ricardo Attar,François Gaudet
View Articletitled, Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Supplemental data

LYMPHOID NEOPLASIA

Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
Debora Soncini,Paola Minetto,Claudia Martinuzzi,Pamela Becherini,Valeria Fenu,Fabio Guolo,Katia Todoerti,Giovanni Calice,Paola Contini,Maurizio Miglino,Giulia Rivoli,Sara Aquino,Alida Dominietto,Antonia Cagnetta,Mario Passalacqua,Santina Bruzzone,Alessio Nencioni,Massimo Zucchetti,Tommaso Ceruti,Antonino Neri,Roberto M. Lemoli,Michele Cea
View Articletitled, Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
Supplemental data
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Clinical Trials & Observations
Stephen Booth,Hannah Plaschkes,Amy A. Kirkwood,Adam Gibb,Patrick Horgan,Claire Higham,Joanna M. Oladipo,Joe Browning,Usman Khan,Bing Tseu,Lucia Chen,John Willan,Julia Wolf,Arief Gunawan,Paul Fields,Tim Ebsworth,Robert Lown,Dominic Gordon-Walker,Nimish Shah,Kim M. Linton,Graham P. Collins,Jaimal Kothari,Catherine Hildyard,Toby A. Eyre
View Articletitled, Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Supplemental data
Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma
Neeraj Jain,Satishkumar Singh,Georgios Laliotis,Amber Hart,Elizabeth Muhowski,Kristyna Kupcova,Tereza Chrbolkova,Tamer Khashab,Sayan Mullick Chowdhury,Anuvrat Sircar,Fazal Shirazi,Ram Kumar Singh,Lapo Alinari,Jiangjiang Zhu,Ondrej Havranek,Philip Tsichlis,Jennifer Woyach,Robert Baiocchi,Felipe Samaniego,Lalit Sehgal
View Articletitled, Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma
Supplemental data
CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia
Anthony Quagliano,Anilkumar Gopalakrishnapillai,E. Anders Kolb,Sonali P. Barwe
View Articletitled, CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia
Supplemental data
Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice
Sanjay Rathod,Manda Ramsey,Fred D. Finkelman,Christian A. Fernandez
View Articletitled, Genetic inhibition of <em>NFATC2</em> attenuates asparaginase hypersensitivity in mice
Supplemental data
Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis
Daisuke Kaji,Yasunori Ota,Yasuharu Sato,Koji Nagafuji,Yasunori Ueda,Masataka Okamoto,Yasushi Terasaki,Naoko Tsuyama,Kosei Matsue,Tomohiro Kinoshita,Go Yamamoto,Shuichi Taniguchi,Shigeru Chiba,Koichi Ohshima,Koji Izutsu
View Articletitled, Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis
Supplemental data
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models
Clinical Trials & Observations
Stefan Alig,Vindi Jurinovic,Mohammad Shahrokh Esfahani,Sarah Haebe,Verena Passerini,Johannes C. Hellmuth,Erik Gaitzsch,William Keay,Natyra Tahiri,Anna Zoellner,Andreas Rosenwald,Wolfram Klapper,Harald Stein,Alfred Feller,German Ott,Annette M. Staiger,Heike Horn,Martin L. Hansmann,Christiane Pott,Michael Unterhalt,Christian Schmidt,Martin Dreyling,Ash A. Alizadeh,Wolfgang Hiddemann,Eva Hoster,Oliver Weigert
View Articletitled, Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models
Supplemental data

MYELOID NEOPLASIA

Thioridazine requires calcium influx to induce MLL-AF6–rearranged AML cell death
Claudia Tregnago,Ambra Da Ros,Elena Porcù,Maddalena Benetton,Manuela Simonato,Luca Simula,Giulia Borella,Katia Polato,Sonia Minuzzo,Giulia Borile,Paola Cogo,Silvia Campello,Alessandro Massi,Romeo Romagnoli,Barbara Buldini,Franco Locatelli,Martina Pigazzi
View Articletitled, Thioridazine requires calcium influx to induce <em>MLL-AF6</em>–rearranged AML cell death
Supplemental data
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F− MPNs
Friederike Pastore,Aishwarya Krishnan,Henrik M. Hammarén,Olli Silvennoinen,Benedict Yan,Ross L. Levine
View Articletitled, <em>JAK2</em>S523L, a novel gain-of-function mutation in a critical autoregulatory residue in <em>JAK2</em>V617F<sup>−</sup> MPNs
Supplemental data

PLATELETS AND THROMBOPOIESIS

Platelets function as an acute viral reservoir during HIV-1 infection by harboring virus and T-cell complex formation
Sydney R. Simpson,Meera V. Singh,Stephen Dewhurst,Giovanni Schifitto,Sanjay B. Maggirwar
View Articletitled, Platelets function as an acute viral reservoir during HIV-1 infection by harboring virus and T-cell complex formation
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study
Jason R. Hodges,Shannon M. Phillips,Sarah Norell,Chinonyelum Nwosu,Hamda Khan,Lingzi Luo,Sherif M. Badawy,Allison King,Paula Tanabe,Marsha Treadwell,Lucia Rojas Smith,Cecelia Calhoun,Jane S. Hankins,Jerlym Porter
View Articletitled, Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study
Supplemental data
HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation
Scott A. Peslak,Eugene Khandros,Peng Huang,Xianjiang Lan,Carly L. Geronimo,Jeremy D. Grevet,Osheiza Abdulmalik,Zhe Zhang,Belinda M. Giardine,Cheryl A. Keller,Junwei Shi,Ross C. Hardison,Gerd A. Blobel
View Articletitled, HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation
Supplemental data

THROMBOSIS AND HEMOSTASIS

Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia
Allyson M. Pishko,Robert K. Andrews,Elizabeth E. Gardiner,Daniel S. Lefler,Adam Cuker
View Articletitled, Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia
Supplemental data
Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke
Ping-Chang Kuo,Wen-Tsan Weng,Barbara A. Scofield,Destin Furnas,Hallel C. Paraiso,Alexander J. Intriago,Kristopher D. Bosi,I-Chen Yu,Jui-Hung Yen
View Articletitled, Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke
Supplemental data
Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia
Moua Yang,Wei Li,Calvin Harberg,Wenjing Chen,Hong Yue,Renan B. Ferreira,Sarah L. Wynia-Smith,Kate S. Carroll,Jacek Zielonka,Robert Flaumenhaft,Roy L. Silverstein,Brian C. Smith
View Articletitled, Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia
Supplemental data
Omega-6 DPA and its 12-lipoxygenase–oxidized lipids regulate platelet reactivity in a nongenomic PPARα-dependent manner
Jennifer Yeung,Reheman Adili,Adriana Yamaguchi,Cody J. Freedman,Angela Chen,Ryan Shami,Aditi Das,Theodore R. Holman,Michael Holinstat
View Articletitled, Omega-6 DPA and its 12-lipoxygenase–oxidized lipids regulate platelet reactivity in a nongenomic PPARα-dependent manner
Supplemental data

TRANSFUSION MEDICINE

A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data
Ti-Cheng Chang,Kelly M. Haupfear,Jing Yu,Evadnie Rampersaud,Vivien A. Sheehan,Jonathan M. Flanagan,Jane S. Hankins,Mitchell J. Weiss,Gang Wu,Sunitha Vege,Connie M. Westhoff,Stella T. Chou,Yan Zheng
View Articletitled, A novel algorithm comprehensively characterizes human <em>RH</em> genes using whole-genome sequencing data
Supplemental data

TRANSPLANTATION

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
Clinical Trials & Observations
Burak Kalin,Yvette van Norden,Michel van Gelder,Dimitri Breems,Johan Maertens,Mojca Jongen-Lavrencic,Annoek E. C. Broers,Eric Braakman,Tim Grob,Wendelien Zeijlemaker,Gert J. Ossenkoppele,Ellen Meijer,Jan J. Cornelissen
View Articletitled, Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
Supplemental data

ERRATUM

Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295-3301.
View Articletitled, Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <em>Blood Adv.</em> 2020;4(14):3295-3301.
All Issues

Advertisement intended for health care professionals

Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice
Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis
In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbbth3/+) mice
Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals